JP2019116474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019116474A5 JP2019116474A5 JP2019012878A JP2019012878A JP2019116474A5 JP 2019116474 A5 JP2019116474 A5 JP 2019116474A5 JP 2019012878 A JP2019012878 A JP 2019012878A JP 2019012878 A JP2019012878 A JP 2019012878A JP 2019116474 A5 JP2019116474 A5 JP 2019116474A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- cancer
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022063412A JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2024043445A JP2024073610A (ja) | 2010-03-26 | 2024-03-19 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31796410P | 2010-03-26 | 2010-03-26 | |
| US61/317,964 | 2010-03-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018061671A Division JP2018117634A (ja) | 2010-03-26 | 2018-03-28 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232781A Division JP2020072681A (ja) | 2010-03-26 | 2019-12-24 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2022063412A Division JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019116474A JP2019116474A (ja) | 2019-07-18 |
| JP2019116474A5 true JP2019116474A5 (2) | 2020-02-13 |
| JP7100595B2 JP7100595B2 (ja) | 2022-07-13 |
Family
ID=44673895
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501520A Active JP5837567B2 (ja) | 2010-03-26 | 2011-03-25 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2014210674A Active JP6463068B2 (ja) | 2010-03-26 | 2014-10-15 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2016080611A Pending JP2016144468A (ja) | 2010-03-26 | 2016-04-13 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2018061671A Withdrawn JP2018117634A (ja) | 2010-03-26 | 2018-03-28 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2019012878A Active JP7100595B2 (ja) | 2010-03-26 | 2019-01-29 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2019232781A Pending JP2020072681A (ja) | 2010-03-26 | 2019-12-24 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2022063412A Pending JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2024043445A Pending JP2024073610A (ja) | 2010-03-26 | 2024-03-19 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501520A Active JP5837567B2 (ja) | 2010-03-26 | 2011-03-25 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2014210674A Active JP6463068B2 (ja) | 2010-03-26 | 2014-10-15 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2016080611A Pending JP2016144468A (ja) | 2010-03-26 | 2016-04-13 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2018061671A Withdrawn JP2018117634A (ja) | 2010-03-26 | 2018-03-28 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232781A Pending JP2020072681A (ja) | 2010-03-26 | 2019-12-24 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2022063412A Pending JP2022088649A (ja) | 2010-03-26 | 2022-04-06 | Ｍｕｃ１６に対する抗体およびその使用方法 |
| JP2024043445A Pending JP2024073610A (ja) | 2010-03-26 | 2024-03-19 | Ｍｕｃ１６に対する抗体およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9169328B2 (2) |
| EP (2) | EP3222632A1 (2) |
| JP (8) | JP5837567B2 (2) |
| AU (1) | AU2011230590C1 (2) |
| CA (4) | CA3002192C (2) |
| DK (1) | DK2552959T3 (2) |
| ES (1) | ES2621874T3 (2) |
| HK (1) | HK1244496A1 (2) |
| HU (1) | HUE032519T2 (2) |
| ME (1) | ME02670B (2) |
| PL (1) | PL2552959T3 (2) |
| PT (1) | PT2552959T (2) |
| WO (1) | WO2011119979A2 (2) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2552959T (pt) | 2010-03-26 | 2017-04-21 | Memorial Sloan Kettering Cancer Center | Anticorpos para muc16 e métodos de utilização dos mesmos |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| PT2961831T (pt) | 2013-02-26 | 2020-10-12 | Memorial Sloan Kettering Cancer Center | Composições e métodos para imunoterapêutica |
| WO2014160368A2 (en) * | 2013-03-13 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
| CN106459990B (zh) * | 2014-02-07 | 2021-06-01 | 麦克马斯特大学 | 三功能t细胞抗原偶联物及其制备方法和用途 |
| EP3107567A4 (en) * | 2014-02-19 | 2017-10-25 | Cangene Corporation | Methods of modulating an immune response |
| BR112017008042A2 (pt) | 2014-10-20 | 2017-12-26 | Juno Therapeutics Inc | métodos e composições para dosagem em terapia de célula adotiva |
| SG10202103475XA (en) * | 2014-12-02 | 2021-05-28 | Prospect Chartercare Rwmc Llc | Methods and compositons for treating cancer |
| CN107667120B (zh) * | 2015-03-17 | 2022-03-08 | 纪念斯隆-凯特林癌症中心 | 抗muc16抗体及其应用 |
| US11261232B2 (en) | 2015-04-02 | 2022-03-01 | Memorial Sloan Kettering Cancer Center | TNFRSF14 / HVEM proteins and methods of use thereof |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| CN108026154B (zh) | 2015-07-01 | 2022-03-08 | 伊玛提克斯生物技术有限公司 | 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物 |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| EP3363814A4 (en) * | 2015-10-14 | 2019-09-25 | Nippon Zenyaku Kogyo Co., Ltd. | CANINE ANTI-TARC ANTIBODY FOR THE TREATMENT AND DIAGNOSIS OF CANINE ATOPIC DERMATITIS |
| EP3842450A1 (en) | 2015-10-23 | 2021-06-30 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| MY194596A (en) * | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| ES2894731T3 (es) | 2017-03-15 | 2022-02-15 | Silverback Therapeutics Inc | Compuestos de benzazepina, conjugados y usos de los mismos |
| WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| WO2018200585A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and secondary effectors and uses thereof |
| CN107557336B (zh) * | 2017-09-15 | 2020-02-14 | 山东兴瑞生物科技有限公司 | 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用 |
| WO2019071358A1 (en) | 2017-10-12 | 2019-04-18 | Mcmaster University | Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| RU2747095C2 (ru) * | 2018-05-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) | Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125 |
| US11319380B2 (en) | 2018-06-04 | 2022-05-03 | Precigen, Inc. | MUC16 specific chimeric antigen receptors and uses thereof |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| BR112021001338A2 (pt) * | 2018-07-26 | 2021-05-04 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr usando proteínas de fusão específicas para o alvo |
| JP2022500413A (ja) | 2018-09-12 | 2022-01-04 | シルバーバック セラピューティックス インコーポレイテッド | Ｔｏｌｌ様受容体アゴニストの抗体コンジュゲート |
| US20200113912A1 (en) | 2018-09-12 | 2020-04-16 | Silverback Therapeutics, Inc. | Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates |
| AU2019337654A1 (en) | 2018-09-12 | 2021-04-08 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| WO2020056194A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| US20210388317A1 (en) * | 2018-10-26 | 2021-12-16 | Shinshu University | High-efficiency method for producing genetically modified cells |
| MX2021005751A (es) * | 2018-11-16 | 2021-10-01 | Memorial Sloan Kettering Cancer Center | Anticuerpos contra mucina 16 y métodos de uso de los mismos. |
| CA3120800A1 (en) | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
| WO2020227538A1 (en) * | 2019-05-08 | 2020-11-12 | Memorial Sloan Kettering Cancer Center | Humanized antibodies to mucin-16 and methods of use thereof |
| WO2021019706A1 (ja) * | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Ｃａｒ発現免疫細胞を含む細胞集団の製造方法 |
| WO2021030665A1 (en) | 2019-08-15 | 2021-02-18 | Silverback Therapeutics, Inc. | Formulations of benzazepine conjugates and uses thereof |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| JP2023532304A (ja) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | 抗ａｓｇｒ１抗体コンジュゲートおよびその使用 |
| AU2021308078A1 (en) | 2020-07-17 | 2023-02-09 | Children's Hospital Los Angeles | Chimeric MyD88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| CA3173810A1 (en) | 2021-06-01 | 2022-12-01 | Andreas Bader | Claudin 18.2 t cell-antigen couplers and uses thereof |
| JP2025525779A (ja) | 2022-07-29 | 2025-08-07 | アロジーン セラピューティクス，インコーポレイテッド | 免疫細胞の認識を低減させるために遺伝子発現が低下した、操作された細胞 |
| WO2025036848A1 (en) | 2023-08-11 | 2025-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Anti-muc16 antibodies and uses thereof |
| CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| CN119978126A (zh) * | 2023-11-10 | 2025-05-13 | 深圳市菲鹏生物治疗股份有限公司 | 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用 |
| TW202523694A (zh) * | 2023-11-17 | 2025-06-16 | 中國大陸商上海藥明生物技術有限公司 | 抗muc16抗體及其用途 |
| WO2025168802A1 (en) | 2024-02-09 | 2025-08-14 | Oslo Universitetssykehus Hf | Chimeric antigen receptor binding to ca125 for treating ovarian cancer |
| CN119638843B (zh) * | 2024-03-20 | 2025-08-26 | 武汉勖瑞生物科技有限责任公司 | 一种抗ca125蛋白的单克隆抗体及其应用 |
| CN118791617B (zh) * | 2024-07-02 | 2025-03-07 | 安徽德合功生物科技有限公司 | Ca125单克隆抗体及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US505713A (en) | 1893-09-26 | Thomas j | ||
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| AU5554190A (en) | 1989-05-08 | 1990-11-29 | Mark I. Farber | Process and apparatus for the recovery of precious metals from slag, tailings and other materials |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5976818A (en) * | 1991-12-16 | 1999-11-02 | The Board Of Trustees Of The University Of Arkansas | Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| WO1995021381A1 (en) | 1994-02-01 | 1995-08-10 | The Rockefeller University | Methods and agents for measuring and controlling multidrug resistance |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| CU22731A1 (es) | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
| US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| AU5062100A (en) | 1999-06-14 | 2001-01-02 | Novo Nordisk A/S | Fviia/tf activity inhibiting compounds |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| ES2276708T3 (es) | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| US6905839B2 (en) | 2002-07-31 | 2005-06-14 | Takashi Furuta | In vivo phenotyping for human cytochrome P450 3A activity |
| GB2424273B (en) * | 2002-11-14 | 2007-06-27 | Univ Nottingham | Method for preparing tumour marker protein |
| AU2004213053C1 (en) | 2003-02-20 | 2009-07-16 | Seagen Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| WO2005105841A2 (en) | 2004-03-12 | 2005-11-10 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
| CN1981054A (zh) | 2004-05-14 | 2007-06-13 | 加利福尼亚大学董事会 | 用抗wnt2单克隆抗体和sirna治疗癌症的方法 |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| NZ563370A (en) | 2005-06-20 | 2010-10-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| EP2144628B1 (en) * | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| PT2552959T (pt) | 2010-03-26 | 2017-04-21 | Memorial Sloan Kettering Cancer Center | Anticorpos para muc16 e métodos de utilização dos mesmos |
| US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
| EP3019872A4 (en) | 2013-07-09 | 2016-06-29 | Univ Nebraska | Novel method for targetting glycoproteins for the treatment of cancer |
| CN107667120B (zh) | 2015-03-17 | 2022-03-08 | 纪念斯隆-凯特林癌症中心 | 抗muc16抗体及其应用 |
-
2011
- 2011-03-25 PT PT117603266T patent/PT2552959T/pt unknown
- 2011-03-25 PL PL11760326T patent/PL2552959T3/pl unknown
- 2011-03-25 EP EP17150631.4A patent/EP3222632A1/en active Pending
- 2011-03-25 CA CA3002192A patent/CA3002192C/en active Active
- 2011-03-25 WO PCT/US2011/030025 patent/WO2011119979A2/en not_active Ceased
- 2011-03-25 CA CA3255551A patent/CA3255551A1/en active Pending
- 2011-03-25 ES ES11760326T patent/ES2621874T3/es active Active
- 2011-03-25 DK DK11760326.6T patent/DK2552959T3/en active
- 2011-03-25 AU AU2011230590A patent/AU2011230590C1/en active Active
- 2011-03-25 HU HUE11760326A patent/HUE032519T2/en unknown
- 2011-03-25 US US13/635,090 patent/US9169328B2/en active Active
- 2011-03-25 CA CA3188287A patent/CA3188287C/en active Active
- 2011-03-25 JP JP2013501520A patent/JP5837567B2/ja active Active
- 2011-03-25 CA CA2793753A patent/CA2793753C/en active Active
- 2011-03-25 ME MEP-2017-89A patent/ME02670B/me unknown
- 2011-03-25 EP EP11760326.6A patent/EP2552959B1/en active Active
-
2014
- 2014-10-15 JP JP2014210674A patent/JP6463068B2/ja active Active
-
2015
- 2015-09-10 US US14/850,675 patent/US9790283B2/en active Active
-
2016
- 2016-04-13 JP JP2016080611A patent/JP2016144468A/ja active Pending
-
2017
- 2017-09-05 US US15/695,311 patent/US10759869B2/en active Active
-
2018
- 2018-03-23 HK HK18104038.6A patent/HK1244496A1/en unknown
- 2018-03-28 JP JP2018061671A patent/JP2018117634A/ja not_active Withdrawn
-
2019
- 2019-01-29 JP JP2019012878A patent/JP7100595B2/ja active Active
- 2019-12-24 JP JP2019232781A patent/JP2020072681A/ja active Pending
-
2020
- 2020-07-28 US US16/941,348 patent/US11834513B2/en active Active
-
2022
- 2022-04-06 JP JP2022063412A patent/JP2022088649A/ja active Pending
-
2024
- 2024-03-19 JP JP2024043445A patent/JP2024073610A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019116474A5 (2) | ||
| JP7562528B2 (ja) | 抗体及びその用途 | |
| JP7150880B2 (ja) | 抗－ｂ７－ｈ３抗体およびその用途 | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| CN107840887B (zh) | 一种新的pd-1单克隆抗体 | |
| JP2019519492A5 (2) | ||
| JP2020510422A5 (2) | ||
| CN112154157A (zh) | 抗ror1抗体及其用途 | |
| JP2018522888A5 (2) | ||
| IL302278A (en) | Combination treatment | |
| US20240301085A1 (en) | Humanized gpc3 antibody and application thereof | |
| KR20160127825A (ko) | 항-mcam 항체 및 관련된 사용 방법 | |
| US20240117035A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| JP2024001073A5 (2) | ||
| RU2018102803A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2021517152A5 (2) | ||
| CN114641504A (zh) | 抗b7h4抗体及其双抗和应用 | |
| CN119213023A (zh) | Ilt3和cd3结合剂以及其使用方法 | |
| JP2023517754A (ja) | 抗ｍｕｃ１－ｓｅａ抗体 | |
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| JP2021529524A5 (2) | ||
| JP7496093B2 (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| CN119053622A (zh) | 一种抗ceacam5和ceacam6抗体及其应用 | |
| JPWO2019175885A5 (2) | ||
| WO2023222135A9 (en) | A method of treating solid tumor |